Subscribe Become an Author Log In

Decisions supported by knowledge


Contact us at to request profile updates/corrections. You must be an official company representative to do so (only requests from corporate emails are accepted).



BenevolentAI uses artificial intelligence to mine and analyse biomedical information, from clinical trails data to academic papers.

Benevolent AI can also use the predictive power of its AI algorithm to design new molecules, extracting new hypothesis based on a knowledge graph composed of over a billion relationships between genes, targets, diseases, proteins and drugs. “When the periodic table of the elements was generated, there were gaps in that table where you know elements had to exist, but they hadn't been discovered,” Hunter says. “We use our knowledge graph like that: what relationship should be present but are not yet known?"

Year Founded
United Kingdom based
$207.0 M
Field/area focus
Chemistry and Biology
Research papers
Data type
  • Publications / patents (unstructured data mining)
  • Imaging data (MRI scans, diagnostics etc)
  • Network biology analysis (omics)
  • EHRs/lab notebooks/databases (structured data mining)
Research Use Case
  • Clinical Trials
  • Data mining / Ontology building
  • Lead Discovery
Therapeutic focus
  • Neuroscience
  • Rare Diseases
Drug Discovery Strategy
  • Structure Based Drug Discovery (SBDD)
  • Phenotypic Drug Discovery (PDD)
Business model
  • Own Drug Discovery Programs
Product type
  • Small molecules

Industry Partnerships

2016Janssendevelop new medicines for hard to treat diseases

Posts Mentioning This Company

How AI Helps Validate Life Science Hypotheses - Nov. 14, 2017
Video gallery
How Big Pharma Adopts AI To Boost Drug Discovery - Oct. 8, 2018
Biopharma Insights
Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery - Sept. 12, 2018
Biopharma Insights